Last reviewed · How we verify
Xibrom and Pred Forte
Xibrom (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, while Pred Forte (prednisolone acetate) is a corticosteroid that suppresses immune and inflammatory responses.
Xibrom (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, while Pred Forte (prednisolone acetate) is a corticosteroid that suppresses immune and inflammatory responses. Used for Post-operative inflammation and pain following cataract surgery, Ocular inflammation associated with ophthalmic surgery.
At a glance
| Generic name | Xibrom and Pred Forte |
|---|---|
| Sponsor | Bp Consulting, Inc |
| Drug class | NSAID (bromfenac) and corticosteroid (prednisolone acetate) combination |
| Target | COX-1/COX-2 (bromfenac); glucocorticoid receptor (prednisolone acetate) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bromfenac works by inhibiting COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis and decreasing ocular inflammation. Prednisolone acetate is a topical corticosteroid that binds to glucocorticoid receptors to suppress inflammatory cytokine production and immune cell activation. Together, these agents provide complementary anti-inflammatory effects for post-operative ocular inflammation.
Approved indications
- Post-operative inflammation and pain following cataract surgery
- Ocular inflammation associated with ophthalmic surgery
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Increased intraocular pressure (with corticosteroid)
- Corneal erosion or delayed healing
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- A Study for Post op Inflammation After Cataract Surgery (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% (PHASE4)
- Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification (PHASE4)
- Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery (PHASE4)
- Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care (PHASE4)
- Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xibrom and Pred Forte CI brief — competitive landscape report
- Xibrom and Pred Forte updates RSS · CI watch RSS
- Bp Consulting, Inc portfolio CI